What should the Introduction contain?

• A. The patient consent templates
• B. The chemical name, active ingredients, pharmacological class, rationale for research, and anticipated indications
• C. The general approach to evaluating the product
• D. The trial's budget

Answer: (B)

The Introduction sets the stage by showing exactly what the investigational product is and why the study is needed. It should identify the product with its chemical name and active ingredients and place it in its pharmacological class to signal its mechanism or therapeutic approach. It then lays out the rationale for the research—what gap or problem exists and what prior data justify proceeding with this trial. Finally, it states the anticipated indications or conditions the product is being studied to treat. This combination helps readers understand the scientific and therapeutic basis for the trial.

Elements like patient consent templates belong in the informed consent materials, a general approach to evaluating the product fits better in the methods or study design context, and the trial’s budget is handled in administrative/budget sections, not the Introduction.